Compared to Estimates, Insmed (INSM) Q2 Earnings: A Look at Key Metrics

Core Insights - Insmed reported $90.34 million in revenue for Q2 2024, a 17% year-over-year increase, and a surprise of +2.71% over the Zacks Consensus Estimate of $87.96 million [1] - The company reported an EPS of -$1.94, which is a decline from -$1.78 a year ago, and a surprise of -59.02% compared to the consensus EPS estimate of -$1.22 [1] Revenue Breakdown - Revenue from Japan was $21.11 million, slightly above the two-analyst average estimate of $21.04 million [3] - Revenue from Europe and the rest of the world was $5.44 million, exceeding the two-analyst average estimate of $4.31 million [4] - Revenue from the U.S. was $63.79 million, surpassing the average estimate of $61.72 million from two analysts [5] Stock Performance - Insmed shares have returned -2.9% over the past month, compared to a -6.5% change in the Zacks S&P 500 composite [5] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [5]